You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Litigation Details for Regeneron Pharmaceuticals Inc. v. Novartis Pharma AG (S.D.N.Y. 2020)


✉ Email this page to a colleague

« Back to Dashboard


Biologic Drugs cited in Regeneron Pharmaceuticals Inc. v. Novartis Pharma AG
The biologic drugs covered by the patent cited in this case are ⤷  Try a Trial and ⤷  Try a Trial .

Details for Regeneron Pharmaceuticals Inc. v. Novartis Pharma AG (S.D.N.Y. 2020)

Date Filed Document No. Description Snippet Link To Document
2020-07-17 1 Complaint succeeded in obtaining a patent—U.S. Patent No. 9,220,631 (the “’631 Patent”)—broadly claiming a PFS …of the ’631 Patent) showing that the claimed PFS in Novartis’s patent was not patentable. Separately,…the patentability of claims of the ’631 Patent. As detailed below, the claims of the ’631 Patent would…material to the patentability of the claims of the ’631 Patent because the ’631 Patent would not have …PFS, Novartis could secure its patent only by ensuring that the U.S. Patent and Trademark Office (“USPTO External link to document
2021-03-01 103 Protective Order (a) “’631 Patent” refers to United States Patent No. 9,220,631. (b) …foreign patents or patent applications, or any other domestic or foreign patent or patent application… or foreign patent or patent application claiming priority to the ’631 Patent or any related… or foreign patent or patent application claiming priority to the ’631 Patent or any related…modifying of patent claims or participation in domestic and/or foreign patent office correspondence External link to document
2021-04-12 112 Exhibit A - ITC Staff Brief of certain claims of U.S. Patent No. 9,220,631 (JX-0001) (“the ’631 patent”) based on the importation….................... 21 IV. U.S. PATENT NO. 9,220,631 ........................................… Public Version IV. U.S. PATENT NO. 9,220,631 A. Claim Construction …syringe. (Id.) D. The ’631 Patent The ’631 patent is titled “SYRINGE” and issued on December…, selling, or importing a patented invention without consent of the patent owner. 35 U.S.C. § 271(a). External link to document
2021-09-21 139 Memorandum & Opinion of the underlying patent application for U.S. Patent No. 9,220,631 (the ‘631 Patent). Id. ¶¶ 8, 256. …the ‘631 Patent “through fraud on the USPTO.” Id. Regeneron alleges that the ‘631 Patent dramatically…Novartis’s patent infringement suit. As outlined above, the enforceability of the ‘631 Patent runs throughout…. The ‘631 Patent “broadly claim[s] a PFS with any anti-VEGF, including EYELEA.” Id. ¶ 8. According to… to Regeneron, the ‘631 Patent is at “the heart of Defendants’ anticompetitive conduct” and a “cornerstone External link to document
2020-12-21 76 Protective Order (a) “’631 Patent” refers to United States Patent No. 9,220,631. (b) …foreign patents or patent applications, or any other domestic or foreign patent or patent application…domestic or foreign patent or patent application claiming priority to the ’631 Patent or any related…domestic or foreign patent or patent application claiming priority to the ’631 Patent or any related…modifying of patent claims or participation in domestic and/or foreign patent office correspondence External link to document
2021-01-24 87 Amended Complaint succeeded in obtaining a patent—U.S. Patent No. 9,220,631 (the “’631 Patent”)—broadly claiming a PFS …of the ’631 Patent) showing that the claimed PFS in Novartis’s patent was not patentable. And unbeknownst…the patentability of claims of the ’631 Patent. As detailed below, the claims of the ’631 Patent would…material to the patentability of the claims of the ’631 Patent because the ’631 Patent would not have …of the ’631 Patent, which is itself unlawful under the patent laws and renders the patent invalid. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.